Title:
BCR-ABL KINASE INHIBITOR AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2015/058661
Kind Code:
A1
Abstract:
The present invention relates to the field of chemical medicines, in particular to compounds as represented by formula I having BCR-ABL kinase inhibitory activity, or pharmaceutically acceptable salt, isomer, solvate, crystal or prodrug thereof, and pharmaceutical composition containing the compounds, and application of the compounds or compositions in drug preparation. The compounds of the present invention have strong inhibitory effect on BCR-ABL kinase, and can be used to treat diseases such as tumors.
Inventors:
WANG YONG (CN)
ZHAO LIWEN (CN)
LIU YANG (CN)
ZHANG JINGZHONG (CN)
WANG DEZHONG (CN)
GAO YIPING (CN)
CHEN HONGYAN (CN)
ZHANG CANG (CN)
ZHANG DI (CN)
ZHAO LIWEN (CN)
LIU YANG (CN)
ZHANG JINGZHONG (CN)
WANG DEZHONG (CN)
GAO YIPING (CN)
CHEN HONGYAN (CN)
ZHANG CANG (CN)
ZHANG DI (CN)
Application Number:
PCT/CN2014/088911
Publication Date:
April 30, 2015
Filing Date:
October 20, 2014
Export Citation:
Assignee:
NANJING SANHOME PHARMACEUTICAL CO LTD (CN)
International Classes:
C07D487/04; A61K31/4985; A61K31/4995; A61P35/00; C07D519/00
Foreign References:
| CN103848829A | 2014-06-11 | |||
| CN103664787A | 2014-03-26 | |||
| CN102775411A | 2012-11-14 |
Other References:
DESAI, B. ET AL.: "Rapid Discovery of a Novel Series of Abl Kinase Inhibitors by Application of an Integrated Microfluidic Synthesis and Screening Platform", JOURNAL OF MEDICINAL CHEMISTRY, vol. 56, no. 7, 26 February 2013 (2013-02-26), pages 3033 - 3047
REN, X. ET AL.: "Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region-Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against [matinib", JOURNAL OF MEDICINAL CHEMISTRY, vol. 56, no. 3, 9 January 2013 (2013-01-09), pages 879 - 894
REN, X. ET AL.: "Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region-Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against [matinib", JOURNAL OF MEDICINAL CHEMISTRY, vol. 56, no. 3, 9 January 2013 (2013-01-09), pages 879 - 894
Attorney, Agent or Firm:
NANJING ZHONGLIAN PATENT AGENCY CO.,LTD et al. (CN)
南京众联专利代理有限公司 (CN)
南京众联专利代理有限公司 (CN)
Download PDF:
Previous Patent: SINGLE-IMPREGNATING-TUBE VACUUM REFINING DEVICE AND USE THEREOF
Next Patent: CAR-COUPLER BUFFER AND RAILWAY CAR
Next Patent: CAR-COUPLER BUFFER AND RAILWAY CAR